BK infection immune-cell treatment after transplant or weak immunity
Part of Genetic & congenital, Immune system & allergy, Infections clinical trials.
This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a hard-to-treat BK virus infection after a stem cell transplant, a solid organ transplant, or due to a primary immune deficiency
- Your BK virus test results are getting worse (or stay high) even after at least 2 weeks of appropriate antiviral therapy
- Or you cannot tolerate BK antivirals because of significant side effects, or you’re known to be resistant to cidofovir
- You are between about 0 and 80 years old, and can participate based on your functional status (not too sick/weak)
- You do NOT have severe recent immune complications: no acute GVHD over grade 2 or extensive chronic GVHD at the time of infusion
- If you can become pregnant, you must have a negative pregnancy test and agree to effective birth control during treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests an “off-the-shelf” type of immune cell therapy made to attack several viruses (EBV, CMV, adenovirus, and BK, and possibly JC) in people who had an allogeneic stem cell transplant and still have ongoing viral infection. It may help your body control the virus when standard treatments have not worked or you cannot tolerate them.
This trial tests an immune therapy made from EBV-targeted T-cells to treat EBV infections that do not improve with standard anti-viral medicines. It may help by strengthening the body’s ability to fight EBV after certain transplants or immune problems.
This early-phase study tests whether immune cells made from a donor (T cells) can treat BK virus infection in people whose immune system is weak after a stem cell transplant or chemotherapy. It may help control the virus causing bladder/urinary symptoms.
This trial tests a new cell therapy (LB-DTK-BKV) for patients who developed a painful BK virus bladder infection after receiving a stem cell transplant and didn't improve with standard treatment. The therapy may help control the virus and reduce bleeding and pain.
This trial tests whether specially trained immune cells (virus-specific T cells) can safely treat stubborn viral infections after a stem cell transplant. It focuses on children and young adults who have not responded to standard antiviral treatments.
This trial tests a treatment using special immune cells (called cytotoxic T lymphocytes) to fight BK or JC virus infections in people with weakened immune systems, such as cancer patients or organ transplant recipients. It may help control the virus and reduce related complications.
Hear when a new Viral Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.